^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AG-1296

    i
    Other names: AG-1296, AG1296, tyrphostin AG 1296
    Company:
    Friedrich-Schiller University of Jena, Wuhan University, Zhejiang University
    Drug class:
    c-KIT inhibitor, FLT3 inhibitor, Tyrosine kinase inhibitor, PDGFR α inhibitor
    Related drugs:
    9ms
    Lysyl Oxidase Promotes the Formation of Vasculogenic Mimicry in Gastric Cancer through PDGF-PDGFR Pathway. (PubMed, J Cancer)
    With inhibition of PDGFRα and PDGFRβ using AG1295 or AG1296, VM formation in gastric cancer cells decreased (P <0.05), but the number of VM structures increased while LOX was added (P < 0.05). LOX partially promotes the formation of VM in gastric cancer through the PDGF-PDGFR signaling pathway.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD34 (CD34 molecule) • LOX (Lysyl Oxidase)
    |
    PDGFRA expression
    |
    AG-1296
    over2years
    Small-molecule inhibitor - tyrphostin AG1296 regulates proliferation, survival and migration of rhabdomyosarcoma cells. (PubMed, J Physiol Pharmacol)
    To conclude, tyrphostin AG1296 is a promising compound in the treatment of alveolar RMS. Undoubtedly, a better knowledge of receptor pathomechanism of tyrosine kinases may contribute to developing new, more effective ways of RMS treatment.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    AG-1296